50 -

50 - Remak E, Charbonneau C, Negrier S, Kim ST, Motzer RJ. Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma. Journal of Clinical Oncology. 2008;26(24):3995-4000.